Education
About Us
Working with TipRanks
Follow Us
Klotho Neurosciences, Inc. (KLTO)
:KLTO
KLTO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.11 - $3.91
Previous CloseN/A
Volume261.47K
Average Volume (3M)2.20M
Market Cap
$29.77M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.53
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding61,374,435
10 Day Avg. Volume3,448,976
30 Day Avg. Volume2,203,700
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Klotho Neurosciences News
KLTO FAQ
What was Klotho Neurosciences, Inc.’s price range in the past 12 months?
Klotho Neurosciences, Inc. lowest stock price was $0.11 and its highest was $3.91 in the past 12 months.
What is Klotho Neurosciences, Inc.’s market cap?
Klotho Neurosciences, Inc.’s market cap is $29.77M.
When is Klotho Neurosciences, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Klotho Neurosciences, Inc.’s earnings last quarter?
Currently, no data Available
Is Klotho Neurosciences, Inc. overvalued?
According to Wall Street analysts Klotho Neurosciences, Inc.’s price is currently Overvalued.
Does Klotho Neurosciences, Inc. pay dividends?
Klotho Neurosciences, Inc. does not currently pay dividends.
What is Klotho Neurosciences, Inc.’s EPS estimate?
Klotho Neurosciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Klotho Neurosciences, Inc. have?
Klotho Neurosciences, Inc. has 61,374,435 shares outstanding.
What happened to Klotho Neurosciences, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Klotho Neurosciences, Inc.?
Currently, no hedge funds are holding shares in KLTO
Klotho Neurosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Increased
By 43.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.67%
12-Months-Change
Fundamentals
Return on Equity
-249.56%
Trailing 12-Months
Asset Growth
227.73%
Trailing 12-Months
Company Description
Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.
Klotho Neurosciences (KLTO) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
ETHZilla Corporation
―
Silo Pharma
―
Alzamend Neuro
―
Longevity Health Holdings
―
60 Degrees Pharmaceuticals, Inc.
―
Ownership Overview
12.35% Insiders
0.24% Mutual Funds
0.16% Other Institutional Investors
86.66% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---